Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24108955 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Ryuta Watanabe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ehime University Hospital, Ehime 791-0204, Japan. Hauptthemen laut MEDLINE: Carcinoma, Neuroendocrine, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Kowa Life Science Foundation, Life Science Foundation of Japan.
Abstract (Originalsprache)
Neuroendocrine prostate carcinoma (NEPC) accounts for less than 1% of prostate neoplasms and has extremely poorer prognosis than the typical androgen receptor pathway-positive adenocarcinoma of the prostate (ARPC). However, very few cases in which de novo NEPC and APRC are diagnosed simultaneously in the same tissue have been reported. We report herein a 78-year-old man of de novo metastatic NEPC coexisting with ARPC treated at Ehime University Hospital. Visium CytAssist Spatial Gene Expression analysis (10× genetics) was performed using formalin-fixed, paraffin-embedded (FFPE) samples. The neuroendocrine signatures were upregulated in NEPC sites, and androgen receptor signatures were upregulated in ARPC sites. TP53, RB1, or PTEN and upregulation of the homologous recombination repair genes at NEPC sites were not downregulated. Urothelial carcinoma markers were not elevated. Meanwhile, Rbfox3 and SFRTM2 levels were downregulated while the levels of the fibrosis markers HGF, HMOX1, ELN, and GREM1 were upregulated in the tumor microenvironment of NEPC. In conclusion, the findings of spatial gene expression analysis in a patient with coexisting ARPC and de novo NEPC are reported. The accumulation of cases and basic data will help with the development of novel treatments for NEPC and improve the prognosis of patients with castration-resistant prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Ehime University Hospital, Ehime 791-0204, Japan.
- Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
- Department of Analytical Pathology, Ehime University Graduate School of Medicine, Ehime 791-0295, Japan.
- Division of Pathology, Proteo-Science Center, Ehime 790-0826, Japan.
- Division of Diagnostic Pathology, Ehime University Hospital, Ehime 791-0204, Japan.
ORCID-Profile: Ryuta Watanabe, Noriyoshi Miura, Tadahiko Kikugawa
Förderung
- Japan Society for the Promotion of Science
- Kowa Life Science Foundation
- Life Science Foundation of Japan
- SGH Foundation
- The Japanese Foundation for Prostate Research
- JSPS KAKENHI
Zitieren
APA
Watanabe, R., Miura, N., Kurata, M., Kitazawa, R., Kikugawa, T., & Saika, T. (2023). Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24108955
Vancouver
Watanabe R, Miura N, Kurata M, Kitazawa R, Kikugawa T, Saika T. Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24108955
BibTeX
@article{Watanabe2023,
author = {Watanabe, Ryuta and Miura, Noriyoshi and Kurata, Mie and Kitazawa, Riko and Kikugawa, Tadahiko and Saika, Takashi},
title = {Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24108955}
}
EUVIMED